These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9916886)

  • 1. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.
    Miller A; Shapiro S; Gershtein R; Kinarty A; Rawashdeh H; Honigman S; Lahat N
    J Neuroimmunol; 1998 Dec; 92(1-2):113-21. PubMed ID: 9916886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.
    Neuhaus O; Farina C; Yassouridis A; Wiendl H; Then Bergh F; Dose T; Wekerle H; Hohlfeld R
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7452-7. PubMed ID: 10861011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
    Oreja-Guevara C; Ramos-Cejudo J; Aroeira LS; Chamorro B; Diez-Tejedor E
    BMC Neurol; 2012 Sep; 12():95. PubMed ID: 22989378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.
    Fellay B; Chofflon M; Juillard C; Paunier AM; Landis T; Roth S; Gougeon ML
    Immunology; 2001 Dec; 104(4):383-91. PubMed ID: 11899423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.
    Ziemssen T; Kümpfel T; Klinkert WE; Neuhaus O; Hohlfeld R
    Brain; 2002 Nov; 125(Pt 11):2381-91. PubMed ID: 12390966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system.
    Aharoni R; Meshorer A; Sela M; Arnon R
    J Neuroimmunol; 2002 May; 126(1-2):58-68. PubMed ID: 12020957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
    Flechter S; Vardi J; Pollak L; Rabey JM
    J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory vaccines against autoimmune diseases.
    Sela M
    Rejuvenation Res; 2006; 9(1):126-33. PubMed ID: 16608409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells.
    Vieira PL; Heystek HC; Wormmeester J; Wierenga EA; Kapsenberg ML
    J Immunol; 2003 May; 170(9):4483-8. PubMed ID: 12707324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients.
    Ersoy E; Kuş CN; Sener U; Coker I; Zorlu Y
    Eur J Neurol; 2005 Mar; 12(3):208-11. PubMed ID: 15693810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.
    Chen M; Gran B; Costello K; Johnson K; Martin R; Dhib-Jalbut S
    Mult Scler; 2001 Aug; 7(4):209-19. PubMed ID: 11548979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.
    Kim HJ; Ifergan I; Antel JP; Seguin R; Duddy M; Lapierre Y; Jalili F; Bar-Or A
    J Immunol; 2004 Jun; 172(11):7144-53. PubMed ID: 15153538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis.
    Al-Shammri S; Rawoot P; Azizieh F; AbuQoora A; Hanna M; Saminathan TR; Raghupathy R
    J Neurol Sci; 2004 Jul; 222(1-2):21-7. PubMed ID: 15240191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells.
    Farina C; Then Bergh F; Albrecht H; Meinl E; Yassouridis A; Neuhaus O; Hohlfeld R
    Brain; 2001 Apr; 124(Pt 4):705-19. PubMed ID: 11287371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
    Dhib-Jalbut S
    Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.